1-(4-oxocyclohexyl)pyrrolidin-2-one | 1352933-85-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-(4-oxocyclohexyl)pyrrolidin-2-one
• CAS: 1352933-85-7
• 化学式: C₁₀H₁₅NO₂
• mdl: MFCD23714792
• 分子量: 181.235
• InChiKey: LITOUEJAJQBLGI-UHFFFAOYSA-N

物化性质

• 沸点：
  357.0±35.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-oxocyclohexyl)pyrrolidin-2-one 在 palladium 10% on activated carbon 、 氨 、 氢气 作用下， 以 甲醇 为溶剂， 生成 1-(4-aminocyclohexyl)pyrrolidin-2-one
  参考文献：
  名称：

  Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors

  摘要：

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.

  DOI：

  10.1021/jm502009h
• 作为产物：
  描述：

  4-羟基环己酮乙二醇缩醛 在 盐酸 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 39.5h， 生成 1-(4-oxocyclohexyl)pyrrolidin-2-one
  参考文献：
  名称：

  [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  [FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE

  摘要：

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。

  公开号：

  WO2011159854A1

文献信息

• OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF
  申请人：Braun Alain

  公开号：US20070149562A1

  公开（公告）日：2007-06-28

  The present invention relates to compounds of formula (I) as defined herein that are melanocortin receptor agonists, to the preparation thereof and to the therapeutic use thereof in the treatment or prevention of a condition selected from obesity, diabetes and sexual dysfunctions that can affect both sexes, in the treatment of cardiovascular diseases, and also in anti-inflammatory uses or in the treatment of alcohol dependency.

  本发明涉及根据本文所定义的式（I）的化合物，这些化合物是黑色素皮质素受体激动剂，涉及其制备以及在治疗或预防肥胖、糖尿病和可能影响两性的性功能障碍中的治疗用途，治疗心血管疾病，以及抗炎症用途或治疗酒精依赖症。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Lanter James C.

  公开号：US20110312936A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 4 , J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涉及I式化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。本发明还涉及一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。本发明还涉及通过给哺乳动物施加至少一种I式化合物的治疗有效量来抑制CCR2活性的方法。
• Cyclohexyl-azetidinyl antagonists of CCR2
  申请人：Janssen Pharmaceutica NV

  公开号：US09062048B2

  公开（公告）日：2015-06-23

  The present invention comprises compounds of Formula I. wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

  本发明涉及公式I的化合物，其中：R1、R2、R4、J、Q和A如规范中所定义。该发明还涉及一种预防、治疗或改善综合症、疾病或疾患的方法，其中所述综合症、疾病或疾患是2型糖尿病、肥胖症和哮喘。该发明还涉及通过给哺乳动物施用公式I中至少一种化合物的治疗有效量来抑制CCR2活性的方法。
• Process for preparing compounds useful as intermediates for the preparation of modulators of chemokine receptor activity
  申请人：Bristol-Myers Squibb Company

  公开号：EP2194051A1

  公开（公告）日：2010-06-09

  The present invention provides a process for preparing compounds of Formula (x): ' Compounds that are useful intermediates of the process are also provided herein.

  本发明提供了一种制备式 (x) 化合物的工艺： '(x)。 本文还提供了作为该工艺有用中间体的化合物。
• DERIVES D'OXOPIPERIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：Sanofi-Aventis

  公开号：EP1773796B1

  公开（公告）日：2010-03-03